Blends
Retatrutide / Cagrilintide
What is it?
This entry combines a GIP/GLP-1/glucagon receptor agonist with an amylin analogue. The attachment identifies the names and a total mass, but not the individual component amounts. It should therefore be treated as a separately specified blend, not as retatrutide alone.
How it is studied
The proposed research rationale involves overlapping appetite and metabolic pathways. Adding another satiety-related compound is not proof of an additive benefit: receptor interactions, tolerability and the physical stability of a mixed preparation all need investigation.
What the evidence shows
Published retatrutide and cagrilintide trials provide background on the individual compounds. They do not establish the efficacy or safety of this particular combination. The sources linked below are component studies, not a clinical trial of the RC10 vial.
Limitations & safety context
The component ratio, exact formulation and blend-specific evidence are absent from the attachment. Clinical findings for cagrilintide–semaglutide cannot be transferred to retatrutide–cagrilintide. Combining biologically active agents can change adverse effects as well as experimental results.
Listed specifications
| Reference | Listed contents |
|---|---|
| RC10 | 10 mg total |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.